This Project Grant award of $356,850 from the National Cancer Institute's Cancer Treatment Research Program (CFDA 93.395) supports a research project at the Medical College of Wisconsin to investigate the use of EGFR inhibitors in colorectal cancer patients with mutant RAS genes. The key objectives are to: 1) Conduct functional mechanistic studies to test RAS mutants and their ability to bind the NF1 tumor suppressor for EGFR inhibitor sensitivity; 2) Pharmacologically target wild-type RAS in...
This Project Grant award of $640,583 from the National Cancer Institute (NCI) under the Cancer Treatment Research (CFDA 93.395) program supports research by Cold Spring Harbor Laboratory (CSHL) to enhance the efficacy of immunotherapy against metastatic colorectal cancer (MCRC). The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their metabolic fitness and anti-tumor activity within the immunosuppressive MCRC tumor microenvironment. The research aims to delineate the...
The National Cancer Institute (NCI) awarded a $439,367 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center (UNMC) Division. The grant, titled "Assessment of Strategies for Targeting Transcriptional Co-Activators in Colorectal Cancer," aims to investigate the role of PGC-1 family proteins, specifically PGC-1B, in promoting the survival of colorectal...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $205,700 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The research will evaluate how intrinsic tumor features contribute to the development of resistance, and test a novel combination approach of DNA repair inhibition and targeted therapy to prevent...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $406,611 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Texas Health Science Center at Houston (UTHealth). The grant, titled "The Role and Therapeutic Targeting of GPR56 in Colorectal Cancer," aims to investigate the function and signaling mechanisms of the GPR56 protein in colorectal cancer progression and therapy resistance. Key objectives include:...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $551,848 to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA to investigate the molecular mechanisms by which the transcription factor SOX9 impairs cell differentiation and drives developmental reprogramming in colorectal cancer (CRC). The research aims to: 1) Use single-cell sequencing analyses to identify regulators of fetal gene...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,827.00 to New York University School of Medicine to conduct research aimed at enhancing the effectiveness of KRAS inhibitor therapy for cancer. The research project, titled "Exploiting Synthetic Lethality to Enhance KRAS Inhibitor Therapy of Cancer," will evaluate specific serine/threonine kinases as synthetic lethal targets to improve the response to KRAS inhibitors like...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625.00 to the University of Pittsburgh to develop and evaluate a nanoparticle-based immunochemotherapy for the treatment of metastatic colorectal cancer. The key objectives are to: 1) Develop and characterize a nanoparticle platform that can co-deliver siRNA targeting the IRHOM1 protein and a chemotherapy agent (CPT-SAHA) to enhance tumor targeting and immune...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award of $560,297 to the Icahn School of Medicine at Mount Sinai supports research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The key objectives are to: Generate phenotypic transcriptional reporters to track the dynamics of LGR5+ cancer stem cells (CSCs) and ONFSCs, and use these to dissect the functional interplay between these stem cell populations. Employ a multi-omic...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is focused on developing innovative RNA nanoparticle and exosome-based technologies to silence the KRAS gene and inhibit metastatic colon cancer. The total award of $497,002 will support research at The Ohio State University, with sub-awards to the University of Houston and the University of Kentucky, to investigate mechanisms for delivering the CRISPR-dCas9-HDAC1 repressor complex and KRAS...